ERBB2 and breast cancer: This possibility is consistent with the finding that pathological complete response after neoadjuvant chemotherapy is a prognostic factor for patients with HER2-overexpressing breast cancer, but it is not a surrogate marker for event-free survival or overall survival, which depends on the tumor size and nodal status [196,197].